RANDOMIZED AND CONTROLLED THERAPEUTICAL ASSAY OF THE VERRUCOSE PHASE OF INFECTION BY BARTONELLA BACILLIFORMIS IN PERU.
Not Applicable
Completed
- Conditions
- -A449 Bartonellosis, unspecifiedBartonellosis, unspecifiedA449
- Registration Number
- PER-085-02
- Lead Sponsor
- IDAD TERRITORIAL DE SALUD CARAZ,
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Age: 1-60 years
Clinical diagnosis
Able to give informed consent
Without exclusion criteria
Stay in the area for 2 months
Exclusion Criteria
Pregnancy
Lactation
Oral contraceptives
Chronic alcohol consumption
Liver disease
Medicines that interact
Admission to the hospital for an unrelated cause
Use of antibiotics in the previous 30 days
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie Bartonella bacilliformis infection in the verrucous phase?
How does PER-085-02 compare to standard-of-care treatments for Bartonellosis in Peru?
Are there specific biomarkers for patient selection in Bartonella bacilliformis clinical trials?
What adverse events are associated with therapies for Bartonella bacilliformis infection?
What combination therapies are being explored for Bartonellosis treatment in clinical research?